News of a significant earnings beat propelled Regeneron Pharmaceuticals (NASDAQ: REGN) to a nearly 5% share price gain on the second trading day of the week. The company posted its fourth-quarter and full-year 2024 results before market open, and investors were clearly impressed by the numbers. Regeneron’s price zoomed well higher than the S&P 500 index’s trajectory, which was a rise of 0.7% on the day.
The quarter saw Regeneron grow its revenue by 10% year over year to just under $3.79 billion. Although non-GAAP (adjusted) net income didn’t rise as precipitously, it did improve, gaining 2% to $1.39 billion. The latter figure shook out to $12.07 per share.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. See the 10 stocks »
That meant a double beat for the pharmaceutical company, especially on the bottom line, as analyst expectations for the period were more modest. Collectively, they were anticipating Regeneron would book $3.76 billion in revenue, filtering down to adjusted net income of $11.27 per share.
Sales of its leading product, retina disorder treatment Eylea, crept up by 2% during the period to bring in slightly under $1.5 billion. Of its remaining product sales, standouts included cancer drug Libtayo, with a robust 50% gain to $367 million. The company’s collaboration revenue derived from partnerships with Sanofi and Bayer rose by 17% to nearly $1.61 billion.
Regeneron also proffered selected guidance for the entirety of 2025. It anticipated spending $5 billion to $5.2 billion on non-GAAP research and development expenses, while capital expenditures should land at $850 million to $975 million. It did not provide revenue or profitability forecasts.
Although that’s a bit atypical, all in all it was a solid earnings report for the company. Its portfolio isn’t large, but it is a good mix of established and up-and-coming products, plus it’s doing well with collaborations and has a robust pipeline. There is much to like about this stock these days.
Before you buy stock in Regeneron Pharmaceuticals, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Regeneron Pharmaceuticals wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you’d have $714,954!*
Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than quadrupled the return of S&P 500 since 2002*.
*Stock Advisor returns as of February 3, 2025
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Regeneron Pharmaceuticals. The Motley Fool has a disclosure policy.
—
Blog powered by G6
Disclaimer! A guest author has made this post. G6 has not checked the post. its content and attachments and under no circumstances will G6 be held responsible or liable in any way for any claims, damages, losses, expenses, costs or liabilities whatsoever (including, without limitation, any direct or indirect damages for loss of profits, business interruption or loss of information) resulting or arising directly or indirectly from your use of or inability to use this website or any websites linked to it, or from your reliance on the information and material on this website, even if the G6 has been advised of the possibility of such damages in advance.
For any inquiries, please contact [email protected]
